5 Key Takeaways
-
1
Pediatric leukemia molecular testing often requires multiple costly, time-consuming assays and substantial infrastructure and expertise.
-
2
These testing requirements can limit comprehensive diagnostics in low-resource settings, including low- and middle-income countries.
-
3
The researchers used long-read nanopore sequencing to generate multimodal leukemia diagnostic data with a low-cost, portable platform.
-
4
The MinION platform can multiplex up to 12 samples per flow cell, with estimated consumables costs of about $100 per case.
-
5
Further validation is underway to assess concordance, or noninferiority, with standard-of-care diagnostics before broader adoption.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

About the Author(s)
Helen Bristow
Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.